Cited 27 times in
Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유철주 | - |
dc.date.accessioned | 2015-06-10T12:52:10Z | - |
dc.date.available | 2015-06-10T12:52:10Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 1545-5009 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/110594 | - |
dc.description.abstract | BACKGROUND: Hyperuricemia accompanying tumor lysis syndrome is a serious complication in neoplasia with rapid proliferation and destruction. To confirm the efficacy of recombinant urate oxidase (rasburicase) and its safety profile, a phase IV compassionate use prospective study was performed in Korean pediatric patients with hematologic malignancies. PROCEDURE: Rasburicase was administered at 0.2 mg/kg/day once daily for 3-5 days (twice daily allowed during the first 72 hr) by intravenous route for hyperuricemia (uric acid > 7.5 mg/dl). The study period was 5 weeks and consisted of a baseline assessment within 48 hr before the administration of rasburicase, 3-5 days of assessment during treatment and a follow-up assessment at 4 weeks after its final administration. RESULTS: The uric acid endpoint (< or =7.0 mg/dl) was reached in 97.3% (36/37) of the patients and uric acid levels were significantly reduced in all patients (P < 0.001). Drug related toxicities were mild and reversible without any grade 4 or serious adverse event associated with rasburicase. CONCLUSION: This study confirms that rasburicase is a safe and effective agent for the treatment of hyperuricemia associated with hematologic malignancies in pediatric patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 439~445 | - |
dc.relation.isPartOf | PEDIATRIC BLOOD & CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hematologic Neoplasms/complications* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hyperuricemia/complications* | - |
dc.subject.MESH | Hyperuricemia/drug therapy* | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Infant, Newborn | - |
dc.subject.MESH | Korea/epidemiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Recombinant Proteins/administration & dosage | - |
dc.subject.MESH | Recombinant Proteins/therapeutic use | - |
dc.subject.MESH | Renal Dialysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Urate Oxidase/administration & dosage | - |
dc.subject.MESH | Urate Oxidase/adverse effects | - |
dc.subject.MESH | Urate Oxidase/therapeutic use* | - |
dc.subject.MESH | Uric Acid/blood | - |
dc.title | Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학) | - |
dc.contributor.googleauthor | Hee Young Shin | - |
dc.contributor.googleauthor | Hyoung Jin Kang | - |
dc.contributor.googleauthor | Eun Sil Park | - |
dc.contributor.googleauthor | Hyoung Soo Choi | - |
dc.contributor.googleauthor | Hyo Seop Ahn | - |
dc.contributor.googleauthor | Sun Young Kim | - |
dc.contributor.googleauthor | Nak Gyun Chung | - |
dc.contributor.googleauthor | Hack Ki Kim | - |
dc.contributor.googleauthor | So Youn Kim | - |
dc.contributor.googleauthor | Hoon Kook | - |
dc.contributor.googleauthor | Tai Ju Hwang | - |
dc.contributor.googleauthor | Kwang Chul Lee | - |
dc.contributor.googleauthor | Sun Min Lee | - |
dc.contributor.googleauthor | Kun Soo Lee | - |
dc.contributor.googleauthor | Keon Hee Yoo | - |
dc.contributor.googleauthor | Hong Hoe Koo | - |
dc.contributor.googleauthor | Mee Jung Lee | - |
dc.contributor.googleauthor | Jong Jin Seo | - |
dc.contributor.googleauthor | Hyung Nam Moon | - |
dc.contributor.googleauthor | Thad Ghim | - |
dc.contributor.googleauthor | Chuhl Joo Lyu | - |
dc.contributor.googleauthor | Won Sik Lee | - |
dc.contributor.googleauthor | Yong Mook Choi | - |
dc.identifier.doi | 10.1002/pbc.20555 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02524 | - |
dc.relation.journalcode | J02479 | - |
dc.identifier.eissn | 1545-5017 | - |
dc.identifier.pmid | 16123985 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1002/pbc.20555/abstract | - |
dc.subject.keyword | compassionate study | - |
dc.subject.keyword | hematologic malignancy | - |
dc.subject.keyword | hyperuricemia | - |
dc.subject.keyword | pediatric patients | - |
dc.subject.keyword | rasburicase tumor lysis syndrome | - |
dc.contributor.alternativeName | Lyu, Chuhl Joo | - |
dc.contributor.affiliatedAuthor | Lyu, Chuhl Joo | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 46 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 439 | - |
dc.citation.endPage | 445 | - |
dc.identifier.bibliographicCitation | PEDIATRIC BLOOD & CANCER, Vol.46(4) : 439-445, 2006 | - |
dc.identifier.rimsid | 57149 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.